Literature DB >> 17116665

Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Susanne Perkhofer1, Helene Lugger, Manfred P Dierich, Cornelia Lass-Flörl.   

Abstract

The MICs and fractional inhibitory concentrations of posaconazole (POS) and voriconazole (VRZ), alone and in combination with amphotericin B (AMB), for the conidia and hyphae of 100 Aspergillus isolates were evaluated. POS-AMB had more synergistic activity against hyphae (75% of isolates) than VRZ-AMB (37%) and significantly more synergistic activity against hyphae than against conidia (12%).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17116665      PMCID： PMC1797736          DOI： 10.1128/AAC.01024-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  The past, present and future of antimycotic combination therapy.

Authors:  A Polak
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

Review 2.  Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.

Authors:  Tiene G M Bauters; Franky M A Buyle; Renaat Peleman; Hugo Robays
Journal:  Pharm World Sci       Date:  2005-02

3.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

Review 4.  Aspergillus fumigatus cell wall: composition and biosynthesis.

Authors:  M Bernard; J P Latgé
Journal:  Med Mycol       Date:  2001       Impact factor: 4.076

5.  In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors:  A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 6.  An overview of fungal infections.

Authors:  G Garber
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

Authors:  Issam I Raad; John R Graybill; Ana Beatriz Bustamante; Oliver A Cornely; Veronica Gaona-Flores; Claude Afif; Donald R Graham; Richard N Greenberg; Susan Hadley; Amelia Langston; Ricardo Negroni; John R Perfect; Punnee Pitisuttithum; Angela Restrepo; Gary Schiller; Lisa Pedicone; Andrew J Ullmann
Journal:  Clin Infect Dis       Date:  2006-05-08       Impact factor: 9.079

8.  Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

Authors:  C Lass-Flörl; M Nagl; C Speth; H Ulmer; M P Dierich; R Würzner
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 9.  Posaconazole: clinical pharmacology and potential for management of fungal infections.

Authors:  Andreas H Groll; Thomas J Walsh
Journal:  Expert Rev Anti Infect Ther       Date:  2005-08       Impact factor: 5.091

10.  Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Authors:  D J Diekema; S A Messer; R J Hollis; R N Jones; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
View more
  6 in total

1.  Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole.

Authors:  Marcelo Sandoval-Denis; F Javier Pastor; Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

2.  Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs.

Authors:  Keigo Kimura; Yoshitsugu Inoue; Seishi Asari; Atsuko Sunada; Yuichi Ohashi; Yoshikazu Shimomura; Chie Sotozono; Hiroshi Hatano; Masahiko Fukuda; Hiroshi Eguchi; Kaoru Araki-Sasaki; Takashi Suzuki; Saichi Hoshi; Toru Tobe; Takashi Yaguchi; Koichi Makimura
Journal:  Jpn J Ophthalmol       Date:  2022-03-29       Impact factor: 2.447

3.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

4.  Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.

Authors:  Susanne Perkhofer; Daniel Jost; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

5.  In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.

Authors:  Adela Martin-Vicente; Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

6.  In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Susanne Perkhofer; Veronika Lechner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.